Oncolytics Biotech Inc. (ONCY) Stock Price & Analysis
Oncolytics Biotech Inc. (ONCY) closed at USD 0.55 on Thursday, October 15, 2026, up 1.75% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.54; the Oct 15, 2026 session ranged USD 0.52–0.59 on volume of 1,295,625 shares. Market capitalization is $71.80M, with a 52-week range of USD 0.44–1.32 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ONCY.md
Key facts (ONCY)
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 4.17 (range 2.86–5.88).
- Total return with dividends: 1Y -53.0% vs S&P 500 +18.1%; 5Y -75.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD -0.08, revenue estimate $0K.
Analysts (ONCY)
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 4.17 (low 2.86, high 5.88).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-19 | HC Wainwright & Co. | Target lowered | Buy | $10 → $5 |
Total return (dividends reinvested) (ONCY)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -53.0% | -75.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -53.1% | -24.4% |
| Volatility (annualized) | 80.0% | 73.9% |
| Max drawdown | -63.0% (Jan 2026→Oct 2026) | -88.9% (Jul 2023→May 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 0.55 |
|---|---|
| Change | ▲ 1.75% (up) |
| Previous Close | USD 0.54 |
| Open | USD 0.55 |
| Day Range | USD 0.52 – 0.59 |
| 52-Week Range | USD 0.44 – 1.32 |
| Volume | 1,295,625 shares |
| Market Cap | $71.80M |
| Exchange | NCM |
Technical Analysis (ONCY)
Nexqual's technical model rates ONCY "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.76 (neutral) |
| vs SMA50 | Below (USD 0.74) |
| MACD | -0.07 (negative) |
Analyst Ratings (ONCY)
Wall Street analysts rate ONCY "Buy" based on 6 analysts, with a mean price target of USD 4.17 (range USD 2.86–5.88), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 4.17 |
| High Target | USD 5.88 |
| Low Target | USD 2.86 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (ONCY)
| Next Earnings Date | 2026-11-16 |
|---|---|
| EPS Estimate | USD -0.08 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.11 vs est -0.08 ▼ miss |
| 2026-03-31 | USD -0.11 vs est -0.06 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.07 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (ONCY)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 1.35 |
| Total Cash | $4.12M |
| Total Debt | $448,000 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (ONCY)
Nexqual rates Oncolytics Biotech Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$27M (TTM) |
| Efficiency | Mixed — No data |
Ownership (ONCY)
| Insider Ownership | +1.66% |
|---|---|
| Institutional Ownership | +9.05% |
| Shares Outstanding | 131.12M |
| Float | 125.05M |
| Short % of Float | +5.75% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (ONCY)
Oncolytics Biotech Inc. is led by Jared Kelly J.D., L.L.M. (age 39), CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Director | Jared Kelly J.D., L.L.M. (age 39) |
|---|---|
| Chief Financial Officer | Kirk J. Look C.A. (age 53) |
| Chief Operating Officer | John McAdory (age 48) |
| Chief Technology Officer | Allison Hagerman P.Eng., P.M.P. (age 41) |
| Director of Investor Relations & Communication | Jon Patton |
Major Backers & Investors (ONCY)
Notable institutional backers of Oncolytics Biotech Inc. include Marshall Wace LLP, Seeds Investor LLC , Xtx Topco Ltd, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Marshall Wace LLP | 0.57% |
| Seeds Investor LLC | 0.2% |
| Xtx Topco Ltd | 0.2% |
| International Assets Investment Management, LLC | 0.15% |
| Connective Capital Management LLC | 0.14% |
| Goldman Sachs | 0.13% |
| Tocqueville Asset Management L.p. | 0.11% |
| Everhart Financial Group, Inc. | 0.11% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt